Northrop Grumman Corporation vs GeneDx Holdings Corp — how do they compare? Northrop Grumman Corporation trades at $577.48 (market cap $81.78B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Northrop Grumman Corporation is far larger — about 33.5× GeneDx Holdings Corp's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NOC | WGS | |
|---|---|---|
Market Cap | $81.78B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $768.02 | $167.51 |
52-Week Low | $496.02 | $34.51 |
Enterprise Value | $95.77B | $2.48B |
Dividend Yield | 1.63% | — |
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $577.11, down 0.13% on the day, with a bullish technical trend supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with a record $105 billion backlog, driven by defense contracts like the Sentinel program. Fundamentals show solid profitability with a 10.48% net income margin and 26.96% ROE, though valuation ratios like P/E of 18.3 are moderate. Recent news highlights a $3 billion missile-interceptor agreement, reinforcing growth prospects.
Outlook remains positive with analyst consensus favoring Buy (57% of ratings) and a $598.57 price target, implying ~4% upside. Key opportunities include sustained defense spending and backlog execution, while risks involve margin pressures from specific programs and geopolitical dependencies. The stock's proximity to its 52-week high suggests cautious optimism amid robust operational performance.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Trailing returns across standard periods
Latest headlines on both assets
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →